Global Microbiome Sequencing Services Market Report 2023: Increasing Demand for Metagenomic Sequencing Drives Growth
29 mai 2023 07h53 HE
|
Research and Markets
Dublin, May 29, 2023 (GLOBE NEWSWIRE) -- The "Global Microbiome Sequencing Services Market by Service (Sample Preparation, Sequencing, Library Preparation), Type (Amplicon Sequencing, Whole Genome...
Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
10 mai 2023 07h00 HE
|
Finch Therapeutics Group, Inc.
SOMERVILLE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio...
Live Biotherapeutic Products And Microbiome CDMO Global Market Report 2023: Sector to Reach $358.07 Million by 2030 at a 41.3% CAGR
09 mai 2023 07h58 HE
|
Research and Markets
Dublin, May 09, 2023 (GLOBE NEWSWIRE) -- The "Live Biotherapeutic Products And Microbiome CDMO Market Size, Share & Trends Analysis Report By Application (C.difficle, Crohns Disease, IBS,...
Microbiome Sequencing Services Global Market Report 2023: Increased Genomic Research and Expanded Uses for Microbiome Sequencing Drives Growth
09 mai 2023 05h18 HE
|
Research and Markets
Dublin, May 09, 2023 (GLOBE NEWSWIRE) -- The "Microbiome Sequencing Services Market Size, Share & Trends Analysis Report By Technology (Sequencing By Synthesis, Sequencing By Ligation, Sanger...
Global Microbiome Competitive Landscape Report 2023: Comprehensive Insights on 130+ Companies and 180+ Drugs
28 avr. 2023 09h53 HE
|
Research and Markets
Dublin, April 28, 2023 (GLOBE NEWSWIRE) -- The "Microbiome - Competitive landscape, 2023" report has been added to ResearchAndMarkets.com's offering.This "Microbiome- Competitive landscape, 2023"...
Finch Therapeutics Announces Executive Leadership Transitions
25 avr. 2023 16h05 HE
|
Finch Therapeutics Group, Inc.
Matthew P. Blischak, an experienced life sciences executive and intellectual property counsel, appointed as Chief Executive Officer effective May 16, 2023; Mark Smith, PhD, to complete his time as CEO...
Pan-Biome Pharmaceuticals, a startup focused on age-related diseases and increasing human healthspan, reports positive results in a preclinical trial of colitis
25 avr. 2023 10h00 HE
|
Pan-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, April 25, 2023 (GLOBE NEWSWIRE) -- Pan-Biome Pharmaceuticals, Inc, a Vancouver based preclinical biopharmaceutical company focused on age-related diseases and extending...
Finch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women’s Hospital and Updates to University of Minnesota License Agreement
18 avr. 2023 16h01 HE
|
Finch Therapeutics Group, Inc.
SOMERVILLE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio...
Verb Biotics announces participation in Ginkgo Bioworks’ annual Ferment conference
18 avr. 2023 11h25 HE
|
Verb Biotics
BOSTON, April 18, 2023 (GLOBE NEWSWIRE) -- Verb Biotics, a microbiome innovation company, today announced that it will be participating as a next-generation biotech innovator at Ferment, Ginkgo...
Axial Therapeutics Announces Age Expansion in Global Phase 2b Clinical Trial for Irritability Associated with Autism Spectrum Disorder (ASD)
04 avr. 2023 08h00 HE
|
Axial Therapeutics
-- Children aged 5 to 17 with autism are now eligible to enroll in the clinical trial of AB-2004, a gut targeted, molecular therapeutic -- -- Novel small molecule microbiome approach focused on...